862174-76-3

Upstream product

• 862175-13-1 (S)-((S)-2-amino-3-methylbutyrylamino)cyclohexylacetic acid methyl ester 
• 862174-60-5 (1R,4R,5R)-3-oxo-2-oxabicyclo[2.2.1]heptane-5-carboxylic acid 
• 862174-66-1 3-oxo-2-oxa-bicyclo[2.2.1]heptane-5-carboxylic acid methyl ester 
• 862259-02-7 trans-(3R,4R)-3,4-bis(methoxycarbonyl)cyclopentanol 
• 862174-67-2 (1R,2R,4S)-2-((S)-1-tert-butoxycarbonyl-butylcarbamoyl)-4-hydroxy-cyclopentanecarboxylic acid methyl ester 
• 862174-68-3 (1R,2R,4S)-2-((S)-1-tert-butoxycarbonyl-butylcarbamoyl)-4-(7-methoxy-2-phenyl-quinolin-4-yloxy)-cyclopentanecarboxylic acid methyl ester 
• 67885-98-7 (1R,2R)-4-hydroxycyclopentane-1,2-dicarboxylic acid 
• 35079-19-7 trans-(1R,2R)-1,2-Bis(methoxycarbonyl)-4-oxocyclopentane 

Relevant academic research and scientific papers

Potent inhibitors of the hepatitis C virus NS3 protease: Use of a novel P2 cyclopentane-derived template

The HCV NS3 protease is essential for replication of the hepatitis C virus (HCV) and therefore constitutes a promising new drug target for anti-HCV therapy. Several potent and promising HCV NS3 protease inhibitors, some of which display low nanomolar acti

HCV NS-3 SERINE PROTEASE INHIBITORS

Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more distal to the nominal cleavage site of the native substrate, which linkage reverses the orientation of peptidic bonds on the distal side relative to those proximal to the cleavage site.